Table 3:

Results of the primary and secondary analyses

	Primary analysis		Secondary analysis
	5-year cumulative costs*	5-year cumulative QALY*	5-year cumulative costs*	5-year cumulative QALY*
Current pathway**
Discounted	€166 918	1.2629	€133 477	1.4740
Not discounted	€181 718	1.3030	€145 426	1.5232
New pathway***
Discounted	€166 928	1.4533	€128 189	1.4864
Not discounted	€181 833	1.5011	€139 663	1.5360
Incremental analysis (new pathway – current pathway)
Discounted	€10	0.1904	−€5 288	0.0124
Not discounted	€115	0.1981	−€5 763	0.0128
Incremental cost-effectiveness ratio (€/QALY)
Discounted	52		−426 093
Not discounted	580		−449 222

*Values rounded for presentation in the table.

**40% CM and 60% nhPD in the primary analysis; 10% CM, 80% ICHD, and 10% nhPD in the secondary analysis.

***20% CM, 20% nhPD, and 60% aPD in the primary analysis; 10% CM, 75% ICHD, 0% nhPD, and 15% aPD in the secondary analysis.